《The New York Times》: Market Gradually Digesting Hormuz Strait Blockade
BlockBeats News, June 4th, according to
The United States, Canada, Brazil, Kazakhstan, Venezuela, and other oil-producing countries are increasing crude oil production. The U.S. Strategic Petroleum Reserve (SPR) continues to release inventory to alleviate the supply gap. At the same time, Saudi Arabia and the United Arab Emirates are diverting some of the transportation demand that originally relied on the Strait of Hormuz through land oil pipelines.
However, the Gulf region's economy is still under significant pressure. Qatar's liquefied natural gas exports are highly dependent on the Strait of Hormuz. The International Monetary Fund (IMF) estimates that its economy may shrink by about 9% this year. The overall economic growth expectations for Gulf countries have also been sharply downgraded.
The constrained energy supply has driven up prices of natural gas, fertilizers, and food, further exacerbating global inflationary pressures. But as the market seeks alternative sources of supply, adjusts consumption structures, and gradually releases new production capacity, the impact of the Hormuz crisis on the market is transitioning from a short-term shock to gradual long-term risk pricing. The future market focus may shift back to liquidity, interest rate policies, and global economic fundamentals.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Morgan Stanley senior bond investor turns bullish on US Treasuries for the first time in ten years
US Stock Movement | SuperX AI Technology (SUPX.US) once fell more than 2.5%, hitting an intraday low of $6.46
SuperX AI Technology's stock price declined, falling more than 2.5% at one point.
BUZZ-Pacira BioSciences participated in a Viatris acquisition deal worth 1.65 billions dollars
Latest Update October 8 – Pacira BioSciences (PCRX.O) shares surged by 44%, hitting a more than three-year high at $36.30. If the rally holds, PCRX is poised for its largest single-day gain on record. Pharmaceutical company Viatris (VTRS.O) will acquire Pacira BioSciences in a $1.65 billion cash deal, offering $36.50 per share. The offer represents a premium of approximately 44.8% over Pacira’s recent closing price of $25.20. The transaction will add Pacira’s non-opioid pain medications Exparel and Zilretta to Viatris' product portfolio. Viatris shares fell 2.6% to $17.04. JPMorgan stated: “We believe this acquisition will not significantly alter VTRS' overall financial profile in the short or long term, and expect Exparel’s sales to gradually decline post-2030 due to generic market entry.” Both parties expect to complete the transaction by the end of 2026. Including intraday fluctuations, PCRX shares have risen 40.2% year-to-date, while VTRS has gained 36.8%. (For the convenience of non-English speakers, Reuters provides automated translations of its reports into several other languages. As automated translation may contain errors or lack the necessary context, Reuters does not guarantee the accuracy of automated translated texts and provides them for readers’ convenience only. Reuters assumes no liability for any damage or losses resulting from the use of automated translation.)
Crypto prices
More
